Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

[1]  G. Mills,et al.  Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. , 2008, Cancer research.

[2]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Winer,et al.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Warren,et al.  BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials , 2007, Clinical Cancer Research.

[5]  Ofra Barnett-Griness,et al.  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. , 2007, The New England journal of medicine.

[6]  M. Privat,et al.  BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel Resistance , 2006, Cell cycle.

[7]  A. Ashworth,et al.  Targeting the DNA repair defect of BRCA tumours. , 2005, Current opinion in pharmacology.

[8]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Johnston,et al.  The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.

[10]  A. Jakubowska,et al.  A high proportion of founder BRCA1 mutations in Polish breast cancer families , 2004, International journal of cancer.

[11]  O. Olopade,et al.  Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.

[12]  S. Sundar,et al.  Platinum-based chemotherapy in metastatic breast cancer: current status. , 2004, Cancer treatment reviews.

[13]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[14]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[15]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[16]  Jinsong Liu,et al.  Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1 , 2003, Oncogene.

[17]  R. Weichselbaum,et al.  The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.

[18]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[19]  J. Sainsbury,et al.  ABC of breast diseases , 2000 .

[20]  M. Uslenghi,et al.  The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.